Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR2 L262_A266delinsD NRAS Q61K |
Therapy | Futibatinib |
Indication/Tumor Type | cholangiocarcinoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 L262_A266delinsD NRAS Q61K | cholangiocarcinoma | predicted - resistant | Futibatinib | Case Reports/Case Series | Actionable | In a retrospective analysis, a cholangiocarcinoma patient harboring FGFR2 L262_A266delinsD progressed on treatment with Lytgobi (futibatinib) and was found to have acquired NRAS Q61K via cell-free DNA (PMID: 39706336; NCT02052778). | 39706336 |
PubMed Id | Reference Title | Details |
---|---|---|
(39706336) | A Model for Decoding Resistance in Precision Oncology: Acquired Resistance to FGFR inhibitors in Cholangiocarcinoma. | Full reference... |